Idiopathic Pulmonary Fibrosis - Peer-to-Peer Dialogue

EVENT CALENDAR

CHEST Outstanding Educational Activity Award

PILOT™ STEERING COMMITTEE

SHARE WITH A FRIEND

The France Foundation was the winner of the Clinical Resource Center Outstanding Educational Activity Award in Professional Development at the 2009 American College of CHEST Physicians Annual Meeting.

Learn more >>

Paul W. Noble, MD, Chairperson
Kevin R. Flaherty, MD
Jeffrey A. Golden, MD
Kevin O. Leslie, MD
Steven D. Nathan, MD
Maria L. Padilla, MD
Glenn D. Rosen, MD
Steven A. Sahn, MD
W. Richard Webb, MD

Learn more >>

Therapy for IPF

What are the latest clinical results for drugs to treat patients with IPF?

Steven D. Nathan, MD
Paul W. Noble, MD
Glenn D. Rosen, MD

What are the current clinical trial enrollment opportunities and how should patients be counseled? What is the role of lung transplantation and does it conflict with clinical trial enrollment?

Steven D. Nathan, MD
Paul W. Noble, MD
Glenn D. Rosen, MD

What are the major comorbidities of IPF and how does the treatment of these conditions impact the management of IPF?

Steven D. Nathan, MD
Paul W. Noble, MD
Glenn D. Rosen, MD

Do you know someone who may be interested in this page? Click the link below:

Peer-to-Peer Dialogue Archive

Peer-to-Peer Dialogue features insightful audio commentary from a multidisciplinary group of experts in interstitial lung disease. Listen in for state-of-the-art information as they address timely, clinically relevant topics identified by the PILOT™ Steering Committee.

Subscribe to Podcast

Download iTunes^®

RSS Feed

PLAY

Question

Faculty

2006-2008 Peer-to-Peer Dialogue

MAC

Question

Faculty

Important Office Testing
	What are the elements of office testing that should be used in the diagnosis and monitoring of IPF? Which tests have an impact on the management or course of the disease?	Harold R. Collard, MD Maria L. Padilla, MD Steven A. Sahn, MD
	How do comorbid conditions affect office testing of patients with IPF? Are there some tests that are particularly useful in distinguishing the possible causes of dyspnea and fatigue?	Harold R. Collard, MD Maria L. Padilla, MD Steven A. Sahn, MD
	What are the elements of office testing that are important in the monitoring of patients with IPF? How do we utilize those tests to follow the course of illness with these patients?	Harold R. Collard, MD Maria L. Padilla, MD Steven A. Sahn, MD
Update on Clinical Trials
	Describe the Inspire trial and its results. Discuss the rate of acute exacerbations in the Inspire trial and the implications for our model of IPF.	Harold R. Collard, MD Paul W. Noble, MD Glenn D. Rosen, MD
	Describe the Bosentan trial and its results. Were appropriate endpoints used and what are the implications for further study?	Harold R. Collard, MD Paul W. Noble, MD Glenn D. Rosen, MD
	Which trial results can we expect in the near future and are any preliminary results available? Which trials are available for enrollment that you recommend?	Harold R. Collard, MD Paul W. Noble, MD Glenn D. Rosen, MD
Pulmonary Rehabilitation (2008)
	How and when should pulmonary rehabilitation be used in the management of IPF?	Steven D. Nathan, MD Maria L. Padilla, MD Steven A. Sahn, MD
	How and when should pulmonary rehabilitation be used in the management of IPF?	Steven D. Nathan, MD Maria L. Padilla, MD Steven A. Sahn, MD
	What is the clinical evidence (in IPF or other pulmonary disorders) that pulmonary rehabilitation has a positive impact on outcomes?	Steven D. Nathan, MD Maria L. Padilla, MD Steven A. Sahn, MD
2008 IPF Expert Roundtable Discussion
	IPF Expert Roundtable Discussion	Harold R. Collard, MD Paul W. Noble, MD Glenn D. Rosen, MD
Acute Exacerbation (2007)
	How do you define acute exacerbation? What do you use as criteria? What are the best predictors of acute exacerbations?	Harold R. Collard, MD Paul W. Noble, MD Steven A. Sahn, MD
	How has the emerging concept of an acute exacerbation changed your clinical management of patients with IPF?	Harold R. Collard, MD Paul W. Noble, MD Steven A. Sahn, MD
	What key points about acute exacerbations should be discussed with your patients and their primary care physicians, and when?	Harold R. Collard, MD Paul W. Noble, MD Steven A. Sahn, MD
Lung Transplantation (2007)
	Did the new lung allocation system change your clinical practice? What are the advantages and difficulties?	Jeffrey A. Golden, MD Steven D. Nathan, MD Maria L. Padilla, MD
	How do you counsel patients considering a surgical lung transplant?	Jeffrey A. Golden, MD Steven D. Nathan, MD Maria L. Padilla, MD
	When to refer a patient for consideration of a lung transplant?	Jeffrey A. Golden, MD Steven D. Nathan, MD Maria L. Padilla, MD
Drug Therapy (2007)
	What is the consensus clinical experience with steroid and immunosuppressive therapy in IPF?	Paul W. Noble, MD Glenn D. Rosen, MD Steven A. Sahn, MD
	What are the current clinical trial enrollment opportunities and how should patients be counseled? When are results of these trials expected and what impact will the results have?	Paul W. Noble, MD Glenn D. Rosen, MD Steven A. Sahn, MD
	What is the best practice for helping patients decide on clinical trial entry, from both scientific and counseling standpoints?	Paul W. Noble, MD Glenn D. Rosen, MD Steven A. Sahn, MD



<< Return to the CME Peer-to-Peer Dialogue